A new study led by Cleveland Clinic researchers suggests that popular GLP-1 weight-loss medications could play an unexpected role in slowing cancer spread.

The findings will be presented at the 2026 ASCO Annual Meeting in Chicago and involve several types of obesity-related cancers.

The research team analyzed data from 12,112 patients diagnosed with cancers ranging from stage 1 to stage 3.

Half of the participants began using GLP-1 drugs, such as semaglutide, tirzepatide, dulaglutide, liraglutide, lixisenatide, or pramlintide, after their diagnosis.

Here's What They're Not Telling You About Your Retirement

The other half were prescribed DPP-4 inhibitor drugs, known as “gliptins,” which served as a comparator group.

According to the study, those receiving GLP-1 medications showed significantly lower progression to stage 4 disease in four major cancer types.

The most substantial difference was recorded in non-small cell lung cancer, which showed a 50 percent reduction in risk compared to the gliptin group.

Breast cancer progression was reduced by 43 percent among GLP-1 users, colorectal cancer by 31 percent, and liver cancer by 38 percent. These results indicated a meaningful difference between the two medication classes for patients with these cancers.

This Could Be the Most Important Video Gun Owners Watch All Year

Dr. Mark David Orland, the study’s lead author and a physician at the Taussig Cancer Institute at Cleveland Clinic, said in a press release that the results offer “early evidence that future studies are worth pursuing.”

He noted the association between GLP-1 use and reduced cancer progression across multiple solid tumor types.

For other cancers, including prostate, pancreatic, and kidney, the researchers observed lower rates of spread among GLP-1 users, but those findings did not reach statistical significance.

In addition to the treatment outcomes, the study looked at tumor biology. It found that tumors expressing higher levels of GLP-1 receptors were associated with better survival outcomes overall.

Patients with these receptor-rich tumors were roughly one-third less likely to die during the study period compared with those whose tumors expressed fewer receptors.

The incidence of side effects was similar for both groups of patients, suggesting that the observed differences in cancer progression were not due to treatment tolerability.

Researchers said the findings point toward the possibility that GLP-1 pathways could influence the way certain cancers grow or spread. However, they emphasized that the exact biological mechanisms remain unclear and must be explored through future research.

Because the study was retrospective and observational, it cannot establish direct cause and effect between GLP-1 drug use and lower cancer progression. Researchers acknowledged these limitations and called for randomized clinical trials to confirm the preliminary observations.

They also noted that factors such as overall health, metabolic improvements, or weight loss among GLP-1 users could have played a role in the slowed progression.

The authors cautioned that additional work would be necessary to separate these potential influences.

For certain cancer types, the researchers said their data might not include enough patients to detect statistical significance.

Nonetheless, the overall trends suggest a potentially important link between GLP-1 treatment and cancer outcomes that merits deeper investigation.

The findings, while early, add to the growing body of research on the broader health effects of GLP-1 medications originally developed for diabetes and later adopted for weight management.